Technical Analysis for CHRO - Chromocell Therapeutics Corporation
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 50 DMA | Bullish | -14.23% | |
| New Uptrend | Bullish | -14.23% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -14.23% | |
| Pocket Pivot | Bullish Swing Setup | -14.23% |
| Alert | Time |
|---|---|
| Fell Below 50 DMA | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
| Down 10% | about 10 hours ago |
| Down 2 ATRs | about 10 hours ago |
| Down 1 ATR | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound is CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as for the treatment of eye pain and neuropathic pain. The company was founded in 2002 and is based in Freehold, New Jersey.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Neuropathic Pain Erythromelalgia Sodium Channel Blockers
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Neuropathic Pain Erythromelalgia Sodium Channel Blockers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.0 |
| 52 Week Low | 1.22 |
| Average Volume | 25,421 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 2.31 |
| 20-Day Moving Average | 1.73 |
| 10-Day Moving Average | 1.88 |
| Average True Range | 0.30 |
| RSI (14) | 55.56 |
| ADX | 39.29 |
| +DI | 30.10 |
| -DI | 13.05 |
| Chandelier Exit (Long, 3 ATRs) | 1.85 |
| Chandelier Exit (Short, 3 ATRs) | 2.12 |
| Upper Bollinger Bands | 2.27 |
| Lower Bollinger Band | 1.19 |
| Percent B (%b) | 0.9 |
| BandWidth | 62.70 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.19 |
| MACD Histogram | 0.1247 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.19 | ||||
| Resistance 3 (R3) | 3.22 | 2.90 | 3.02 | ||
| Resistance 2 (R2) | 2.90 | 2.64 | 2.89 | 2.96 | |
| Resistance 1 (R1) | 2.54 | 2.48 | 2.38 | 2.51 | 2.91 |
| Pivot Point | 2.22 | 2.22 | 2.15 | 2.21 | 2.22 |
| Support 1 (S1) | 1.86 | 1.96 | 1.70 | 1.83 | 1.43 |
| Support 2 (S2) | 1.54 | 1.80 | 1.53 | 1.38 | |
| Support 3 (S3) | 1.18 | 1.54 | 1.32 | ||
| Support 4 (S4) | 1.15 |
